Biofil Chemicals & Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
BIOFILCHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.0 pts less than Nifty Microcap 250 and 5.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Biofil Chemicals & Pharmaceuticals reported its Q3 FY26 results on February 13, 2026, showing a dramatic sequential revenue collapse to just ₹85.63 lakhs from ₹1,354.08 lakhs in Q2 FY26, as the company's factory underwent renovation and upgradation for Schedule M (Drugs & Cosmetics Rules) compliance, partially disrupting manufacturing. For the nine months ended December 2025, revenue from operations declined about 17% year-on-year to ₹2,082.96 lakhs (vs ₹2,505.12 lakhs in 9M FY25). Despite weak operations, 9M profit after tax surged to ₹257.37 lakhs from ₹35.81 lakhs, almost entirely driven by a non-operating 'Other Unallocable Income' of about ₹291 lakhs. The statutory auditor (Maheshwari & Gupta) issued an unmodified review opinion. The Pharma segment posted a loss of ₹10.45 lakhs in Q3, while the Chemicals division remained profitable at ₹16.73 lakhs. Q3 EPS stood at ₹0.05.
The headline PAT jump looks impressive but is misleading since it is propped up by a one-time non-operating gain rather than core business performance. Real operations are under pressure with revenue sharply down and the Pharma segment loss-making in Q3, though the factory upgrade is a necessary step. Shareholders should not read the 9M profit growth as a sign of sustainable business momentum; the negative reserves (₹-125.42 lakhs as of March 2025) are also a lingering concern.